For instance, CFTR inhibition could reduce cyst growth and kidney enlargement in patients with autosomal dominant polycystic kidney disease (ADPKD), suggesting that ABBV-2737 may be repurposed for other diseases where CFTR inhibition is advantageous. This evidence concerns the gene CFTR and autosomal dominant polycystic kidney disease.